Extreme Pulmonary Fibrosis: A Case Study

Pulmonary Fibrosis is a serious disease that claims and terrorizes thousands of lives and families. Due to severity of the disease two Senators have decided to introduce an Act that is dedicated to this horrifying disease (the Pulmonary Fibrosis Research Enhancement Act (PFREA)). After the onset of symptoms of pulmonary fibrosis, a person has about 5 years of lifespan, that’s taking in consideration treatment that will be given to the patient. About 30 present of patient that receive treatment for pulmonary fibrosis with oral glucocorticoids will see improvement in their lung function. There are many studies that are being to find a cure for the disease or find a way to present it, unfortunately the studies are still on going

Since they have an excessive amount of mucus in their lungs, it causes them to not eat and lose a large amount of weight. Today, we have different treatment options pertaining to each individual with the disease. One treatment plan is the airways clearance, where a patient wears an inflatable vest that vibrates the chest area. This helps loosen up the lungs and lowers the mucus count in the lungs. Another form of treatment is vaccination. Cystic Fibrosis opens up a patient to a widespread of infections, since there bodies cannot fight off infections. Giving vaccines that prevent pneumonia or the flu can save the patient from developing these infections. Lastly, prescribing antibiotics and cough medicine. Since the lungs are always filled up with mucus, the patient is always prone to coughing because of all the buildup. Cough medicine will reduce the periods of coughing and clear up some of the mucus built up. This disease is extremely deadly if the right medications and treatment plans are not administered properly.

The most important treatment is to quit smoking, if you are a smoker, and your doctor will assist you with the program that can help you to quit, and avoid other lungs irritants. There are also medications that can help to relieve your symptoms like bronchodilators depending on the severity of your COPD, as there is short acting and long acting bronchodilators. These bronchodilators are used through inhaler which helps to deliver the medicine into your lungs. If your COPD is severe and flare up more often the Pulmonologist (doctor who studies and treats the disease of the lungs) may combine Glucocorticosteroids (steroid) with your bronchodilator inhaler. Diets and exercises also plays major roles in the treatments of COPD, meanwhile, you may be restricted from eating certain foods or eating less, or frequently to prevent symptoms to flare up. Moderate exercise can also be suggested to strengthen the muscle of your lungs and to increase your overall

Further information obtained by the auscultation of the patient 's lung indicated secretion build up causing diminished lungs sound. Shortness of Breath was evident when the patient spoke and the use of accessory muscles was apparent as I observed the respiratory rate at 23 breaths a minute. The chest was bilaterally symmetric as the patient breath. On room air, the patient’s oxygen saturation level was 87 percent. The patient spirometer results show FEV1 was at 55 percent. The inability of the patient’s lung to efficiently exchange gas lead to the patient’s SOB.

Pulmonary hypertension is a condition defined by an increase of mean pulmonary artery pressure (pPA) greater than 25mmHG at rest in the absence of associated causes of pulmonary hypertension, and has been classified into five different etiopathogenic groups (Roldan et al., 2014 & Wardle & Tulloh, 2013). The focus of this paper will be on the pathophysiology and treatment of idiopathic pulmonary artery hypertension (IPAH), also referred as primary pulmonary hypertension, in children.

Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and life-threatening, interstitial lung disease of unknown etiology that has no cure (1). The median survival of patients with IPF is only 2 to 3 years. Respiratory failure resulting from this disease progression is the most frequent cause of death. Continuous damage to the alveolar epithelium and concomitant alveolar type II (ATII) cell apoptosis are thought to lead to fibroblast recruitment, accumulation and proliferation and contribute to the perpetuation of the fibrotic scarring and IPF development. ATII cells synthesize, store, and secrete

Nurse Vincent M. Vacca, Jr. aptly described in this issue of the Nursing Journal the significance of early detection and health management of people who are or are maybe suffering from Pulmonary Arterial Hypertension. He described PAH as a condition wherein a patient is having a mean pulmonary arterial (PA) pressure of greater than 25 mm

On examination, he was saturating at 96% on room air. His lung fields revealed reduced air entry but no significant wheeze or

It has been proposed that pulmonary vasoconstriction occurs as an early event of PAH, and is due to abnormal potassium channel expression and endothelial dysfunction. The endothelium is a key regulator of vascular tone and subsequently blood pressure. Endothelial dysfunction results in chronic release of vasoconstrictive agents such as endothelin-1 (ET-1) and impaired production of vasodilatory agents such as nitric oxide (NO) and prostacyclin(2). The effects of the sustained increase in ET-1 seen in PAH makes this molecule a major pharmacological

1 or I ? Early fibrosis involving at least one bronchiole; inflammation similar to that caused by cigarette smoking

Idiopathic pulmonary fibrosis is a progressive lung disease of unknown cause that to date has no pharmacologic

Emphysema: Emphysema is chronic lung disease, which lasts in the long-term. The air sacs, also known as the alveoli in the lungs are damaged. When the air sacs are damaged, their size increases. Less oxygen is carried to the blood. The result of this is shortness of breathing which gets worse

In COPD most attention has focused on the chronic obstructive bronchitis with fibrosis and obstruction of small airways, alveolar wall destruction (emphysema) with enlargement of airspaces and destruction of lung parenchyma, loss of lung elasticity and closure of small airways [152].

As we know that pulmonary fibrosis is a restrictive disease. People who are suffered from pulmonary fibrosis lives a difficult life as they have trouble taking air in to the lungs. The major symptom related to this disease is dyspnea. In common terms, pulmonary fibrosis is considered as scarring in the lungs. The scar in the lungs makes it difficult for oxygen to get into the blood. It also makes difficult for the patient to feel short of breath especially during exercise or walking. I support the idea of pulmonary rehabilitation to improve quality of life and strengthen muscles. It was a great review to know about different oxygen cylinders. I have never changed the regulator of H cylinder, but I would definitely want to learn about it. I

Pulmonary fibrosis is a subset of interstitial lung disease (ILD), a general category that includes various lung conditions. These disorders affect the absorption of oxygen into the lungs and impede normal breathing. Pulmonary fibrosis, like other interstitial lung diseases, affect the interstitium, the lace-like network of tissues that provides support to the lungs’ tiny air sacs, or alveoli. Tiny blood vessels travel through the interstitium, allowing gas exchange between the blood and lungs. Normally, the interstitium is too delicate to be seen in a chest x-ray or CT scan, but interstitial lung diseases like pulmonary fibrosis cause the interstitium to thicken due to scarring, extra fluid or inflammation. If you suspect you or someone you